Scarica l'app Stockscreener
248.94
0.06%
-0.1542
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$248.79
Aprire:
$247.46
Volume 24 ore:
112.51K
Relative Volume:
0.14
Capitalizzazione di mercato:
$32.09B
Reddito:
$2.09B
Utile/perdita netta:
$-332.26M
Rapporto P/E:
-60.13
EPS:
-4.14
Flusso di cassa netto:
$16.06M
1 W Prestazione:
-3.60%
1M Prestazione:
-14.86%
6M Prestazione:
+66.17%
1 anno Prestazione:
+51.90%
Intervallo 1D:
$246.26
$250.71
Intervallo di 1 settimana:
$229.85
$254.17
Portata 52W:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ALNY | 248.88 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| VRTX | 447.55 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.92 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| BNTX | 103.41 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Holdings Lifted by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Banque Cantonale Vaudoise Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Victory Capital Management Inc. Has $11.80 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Empowered Funds LLC Buys 5,362 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Biodefense Market to Witness Huge Growth by 2031: Achaogen Inc., - openPR
Alnylam Pharmaceuticals' (ALNY) Outperform Rating Reiterated at William Blair - MarketBeat
Jefferies Taps Former Alnylam CEO Maraganore as Senior Adviser - BNN Bloomberg
Old drugs shed new light on a rare skin disease - Drug Discovery News
10 Biggest Biotechnology Companies - Investopedia
Alnylam Pharmaceuticals' (ALNY) Buy Rating Reiterated at HC Wainwright - MarketBeat
Piper Sandler Reiterates Overweight Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis - Seeking Alpha
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Trimmed by LMR Partners LLP - MarketBeat
Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment - Clinical Trials Arena
Alnylam's Nucresiran Achieves 96% TTR Reduction in Phase 1 ATTR Amyloidosis Trial | ALNY Stock News - StockTitan
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $294.50 Consensus Price Target from Analysts - MarketBeat
Alnylam Pharmaceuticals Enters Oversold Territory (ALNY) - Nasdaq
Primary Hyperoxaluria Treatment Market Outlook by Examining - openPR
Alnylam Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com India
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Down 23.6% in October - MarketBeat
Alnylam Says It's Not A 'Patent Troll' In Vax IP Row - Law360
FMR LLC Expands Stake in Alnylam Pharmaceuticals - GuruFocus.com
Alnylam downgraded at Wolfe on doubts over Amvuttra growth - MSN
Alnylam Pharmaceuticals To Present At UBS Global Healthcare Conference; Webcast At 11:45 AM ET - Nasdaq
Baillie Gifford & Co. Decreases Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Lowered by Wolfe Research - MarketBeat
Los Angeles Capital Management LLC Has $37.68 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Trading (ALNY) With Integrated Risk Controls - Stock Traders Daily
5,283 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by New York State Teachers Retirement System - MarketBeat
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks - Benzinga
Wellington Management Group LLP's Strategic Reduction in Alnylam Pharmaceuticals Inc - GuruFocus.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Increased by AIA Group Ltd - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by State of Alaska Department of Revenue - MarketBeat
What is HC Wainwright's Forecast for ALNY FY2024 Earnings? - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat
An RNAi renaissance is creating a new generation of startups - BioPharma Dive
Upcoming Opportunities in Hereditary Amyloidosis Market: - openPR
Asset Management One Co. Ltd. Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Van ECK Associates Corp Sells 3,539 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Hemoglobinopathies Market Growth Analysis: Industry - openPR
Alnylam's SWOT analysis: biotech stock poised for growth in ATTR-CM market - Investing.com
Alnylam launches Phase 1 trial of ALN-HTT02 for Huntington’s - Huntington's Disease News
New York State Common Retirement Fund Sells 3,724,457 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. Promotes Cynthia Clayton to Vice President of Investor Relations and Corporate Communications - Marketscreener.com
Alnylam shares remain Buy-rated at H.C. Wainwright, target held steady amid ATTR-CM updates - Investing.com UK
Alnylam to Webcast Presentations at Upcoming November Investor Conferences - StockTitan
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Holdings Boosted by Wealth Enhancement Advisory Services LLC - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Quarterly Earnings Results - MarketBeat
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down - MSN
Silvant Capital Management LLC Has $4.45 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alnylam Pharmaceuticals Inc Azioni (ALNY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Aug 20 '24 |
Sale |
280.00 |
15,000 |
4,200,000 |
73,441 |
0.82%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):